

# About Authorship and Contributions

Version 6.0 (February 2025)

With the aim of ensuring fairness in the rights and responsibilities of authorship for manuscripts generated using the GLADEL databases (GLADEL original and GLADEL 2.0), as well as their corresponding presentations and publications, the following guidelines are established regarding Authorship and Standard Operating Procedures.

## ANNEX I. GLADEL – STRUCTURE AND REGULATIONS

### 7) About Authorship and Contributions

#### 7.1. Original Cohort Launch Project

- The authors of the first publication(s) of the GLADEL and GLADEL 2.0 cohorts (cohort launch publication[s]) will be headed by the intellectual authors and collaborators of the original project, followed by the participating investigators of the cohort(s) used to develop the project, up to the maximum number of authors allowed by the journal selected for publication.
- The order of authorship will be related to the number of patients enrolled in the cohort, as well as the quality of the information, as evaluated by the Data Control Committee.
- All other investigators from the centers will be included in an Appendix at the end of the publication.

#### 7.2. Projects Sponsored by Pro&Pub

- The list of authors will be led by the principal author and a maximum of five collaborators of the project, including the mentor (who will be listed either as the second author or the last author). The designation of the corresponding author will be assigned to the Principal Investigator (PI) or the mentor, as established by consensus of the working group.
- In the second line, the principal investigators of the participating centers of the GLADEL cohort used to conduct the study, or the person they designate, must be included, up to the maximum number allowed by the selected journal or congress.

- The order of authorship will be related to the number of patients enrolled in the cohort, as well as the quality of the information, as evaluated by the Data Control Committee.
- All other investigators from the centers will be included in an appendix as part of the “GLADEL Consortium”, at the end of the publication (see regulations and SOPs, Version 3.0).
- Approval from all authors will be required for scientific outputs, whether for journal publications or conference presentations, through a platform external to GLADEL. For this purpose, the abstract or manuscript must be completed and submitted to GLADEL **30 days** prior to the submission deadline of the selected congress or journal.
- The principal investigator of each center will be responsible for assigning the name of the author who will appear in each publication. The GLADEL Secretariat will contact them to obtain this information.

### 7.3. Additional Projects

- Centers are encouraged to submit “Additional Projects” using the databases of the GLADEL and GLADEL 2.0 cohorts.
- **Submission format:** Every additional project must be submitted to the GLADEL Scientific Committee using the format specifically designed for this purpose (see attached: GLADEL – PRESENTATION OF RESEARCH PROJECTS STANDARD OPERATING PROCEDURES (SOP), Version 3.0 (2025 – English)).
- **Scientific Committee:** The Scientific Committee will consist of three members whose responsibilities will include:
  - a. reviewing and approving projects submitted to GLADEL
  - b. quarterly follow-up of accepted projects with reporting to the Executive Council
  - c. reviewing final manuscripts prior to publication
  - d. suggesting journals, assisting with English editing, etc.
- **Maximum project duration:** A maximum period of 12 months is established for the completion of each project, starting from the date of approval by the Scientific Committee.
- **Authors:** Investigators of an additional project that has been accepted by the Scientific Committee will be the authors of the presentations and/or publications generated from that project. The order of authors in these presentations and/or publications must be agreed a priori by each working group. If the contribution of more than one author is considered equal, shared first authorship may be established.



- **Responsibility of the lead authors:** The lead authors of an additional project are responsible for fulfilling all stages of the research and publication process, adhering to the established timeline, submitting progress reports to the Scientific Committee, and publishing the study in a timely manner. This includes sending the manuscript to all co-authors for review and approval, submitting the manuscript to the selected indexed journal platform, and responding to reviewers' comments until final acceptance for publication.
- **Number of authors:** It is well known that scientific journals currently limit the total number of authors per publication. For this reason, GLADEL encourages additional projects as opportunities for its members to conduct studies using GLADEL cohort data and disseminate them through publications in indexed journals.
- **Author appendix:** All centers and/or investigators who only contributed data or samples to the project(s) will be listed in an Appendix as part of the “**GLADEL Consortium**”.
- **Center ranking:** GLADEL will establish a score for participating centers, determined by the number of patients and the quality of the data contributed to each database. In all additional studies submitted for publication, the total number of authors allowed—after the principal authors of the project—will be filled by principal or associate investigators who rank highest in this classification list, until the author limit of the selected journal is reached. In subsequent publications, investigators ranked next in the list will be included, and so on, until all GLADEL centers have been represented. The cycle then restarts with the following publication.
- **Authorship conflicts:** In cases of authorship conflict, the Scientific Committee will act as mediator and judge between the parties, and its decision will be final and non-appealable. Members of the Scientific Committee involved as authors will be excluded from voting and will be replaced—by random selection—by other members of the Scientific Committee and/or GLADEL investigators.
- **ARTHROS Software:** The ARTHROS Software (version used) must be cited in the Materials and Methods section of all presentations and/or publications derived from the GLADEL database.
- **PANLAR:** As the PANLAR Lupus Study Group, GLADEL commits to acknowledging PANLAR in the acknowledgments section.

### 7.3. Collaborative Projects

- The international recognition of GLADEL has allowed its cohorts (GLADEL and GLADEL 2.0) to be invited to participate in multicenter, multinational collaborative projects.
- In these cases, the number of GLADEL authors will depend on the scope of the collaborative project and the number of authors permitted for each publication.
- As a rule, GLADEL will aim to include the maximum possible number of authors in each publication and rotate authorship to maintain balance in participation, as defined by the principal investigator of each center.
- Whenever possible, all participants will also be listed in a collaborator appendix.

### 7.4. Projects Funded by the Pharmaceutical Industry

- When a project is sponsored by the pharmaceutical industry or another organization external to GLADEL, a limited number of authors from that company or organization may be included, as agreed between the parties.
- Approval from all authors will be required for scientific outputs (journal publications or conference presentations) through a platform external to GLADEL. For this purpose, the abstract or manuscript must be completed and submitted to GLADEL **30 days** prior to the submission deadline of the selected congress or journal. Compliance with these timelines is necessary to ensure proper feedback among authors.
- In all cases, the sponsor will be acknowledged, specifying the type of funding received (unrestricted grant, investigator-initiated project, etc.).

